Al-Kuraishy Hayder M, Al-Gareeb Ali I
Department of Pharmacology, Toxicology and Medicine, College of Medicine, Al-Mustansiriyah University, Baghdad, Iraq.
Adv Biomed Res. 2017 Jun 6;6:69. doi: 10.4103/2277-9175.190994. eCollection 2017.
Trimetazidine is a fatty oxidation inhibitor, leading to shifting of energy substrate from fatty acid oxidation toward glucose oxidation that leads to the reduction of oxygen requirement. The aims of the present study were to elucidate the effects of trimetazidine on psychomotor performance and vigilance on normal healthy volunteers.
A total of 234 subjects (age 22-25 years) were recruited in this study. The volunteers were randomizing into two groups with 117 volunteers in each group. Group I received an inert starch capsule served as a control, and Group II received trimetazidine tablet 15 mg/day. The duration of therapy was 5 days. Test procedure was done at 9.00 a.m. on the psychomotor tester. Before the drug administration, prescore values were recorded and then after 5 days of therapy, the postscore values were recorded.
The placebo did not demonstrate a significant effect on all psychomotor performances and flicker-fusion elements ( > 0.05). Trimetazidine therapy produced a highly significant effect on all components of psychomotor performances and flicker-fusion parameters ( < 0.001) compared with pretreatment era.
We conclude that trimetazidine improves psychomotor performance and vigilance in normal healthy volunteers through advancing total reaction time and critical flicker-fusion frequency.
曲美他嗪是一种脂肪酸氧化抑制剂，可使能量底物从脂肪酸氧化转向葡萄糖氧化，从而降低氧需求。本研究的目的是阐明曲美他嗪对正常健康志愿者精神运动表现和警觉性的影响。
本研究共招募了234名受试者（年龄22 - 25岁）。志愿者被随机分为两组，每组117名。第一组服用惰性淀粉胶囊作为对照，第二组服用曲美他嗪片，每日15毫克。治疗持续时间为5天。测试程序于上午9点在精神运动测试仪上进行。给药前记录预评分值，治疗5天后记录后评分值。
安慰剂对所有精神运动表现和闪光融合指标均未显示出显著影响（>0.05）。与治疗前相比，曲美他嗪治疗对精神运动表现的所有成分和闪光融合参数均产生了高度显著的影响（<0.001）。
我们得出结论，曲美他嗪通过缩短总反应时间和提高临界闪光融合频率来改善正常健康志愿者的精神运动表现和警觉性。
